JOSEPH HOLLEY: Open Payments
NPI 1184077208 · DECATUR, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,451 in 138 payments from 12 companies in 2025. Trend: 2023 $1,984 · 2024 $2,477 · 2025 $6,451
Food & beverage: $3,018Consulting: $2,616Travel & lodging: $817
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 17 | $3,848 |
| ABBVIE INC. | 36 | $889 |
| Madrigal Pharmaceuticals | 13 | $490 |
| Janssen Biotech, Inc. | 16 | $310 |
| Ardelyx, Inc. | 13 | $245 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $162 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $152 |
| Regeneron Healthcare Solutions, Inc. | 5 | $116 |
| Phathom Pharmaceuticals, Inc. | 13 | $103 |
| Gilead Sciences, Inc. | 2 | $50 |
Products named: REZDIFFRA, RINVOQ, DUPIXENT, SKYRIZI, TREMFYA, IBSRELA, ENTYVIO, XIFAXAN.
Industry payments across AL — which companies pay providers there.
